Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted Fast Track Designation by the United States Food and Drug Administration (FDA). This designation, aimed at expediting the development of drugs intended to address unmet medical needs in serious conditions, could provide an advantage in treating advanced […]
Syngene International Ltd. (NSE: SYNGENE), a prominent global contract research, development, and manufacturing organization (CRDMO), has announced the launch of a new protein production platform. This innovative platform integrates cell line and transposon-based technology, licensed from the Swiss biotech services company ExcellGene, with Syngene’s own sophisticated clone selection and development processes. This integration promises a […]
WuXi Biologics (“WuXi Bio”), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a strategic partnership with Toregem BioPharma, a biotech startup emerging from Kyoto University. This collaboration is set to accelerate the development of TRG035, a promising monoclonal antibody targeting USAG-1 for the treatment of congenital adentia, commonly known as tooth […]
Evox Therapeutics, an innovative biotechnology company spun out from Oxford University, has successfully raised £35.5 million in a Series B financing round. The round was led by Redmile Group, with notable new investments from Google’s GV, Cowen Healthcare Investments, and several others. This funding follows a previous £10 million raised from Oxford Sciences Innovation during […]
Modus Therapeutics, a Swedish biotech firm specializing in sickle cell disease therapies, has successfully raised SEK 140 million ($15.76 million) in a funding round spearheaded by HealthCap, a leading European venture capital firm known for investing in innovative therapies for diseases with significant unmet medical needs. The Series A funding round saw HealthCap contribute SEK […]